Health care providers should not use non-invasive prenatal screening tests alone to diagnose genetic abnormalities due to the potential for false results, the Food and Drug Administration warned last week. Also known as cell-free DNA tests or non-invasive prenatal tests, these laboratory developed tests in most cases are not reviewed by the FDA.

“Patients and health care providers should be aware of the risks and limitations of using these genetic prenatal screening tests and that they should not be used alone to diagnose chromosomal (genetic) abnormalities,” FDA said, citing reports that some patients and providers have made critical health care decisions based on the results without additional confirmatory testing. 

Related News Articles

Headline
Joy Lewis, AHA senior vice president of health equity strategies and executive director of AHA’s Institute for Diversity and Health Equity, shared the stage…
Headline
The Department of Health and Human Services July 23 released an amendment to a 2013 emergency declaration under the Food, Drug and Cosmetic Act that broadens…
Headline
The AHA July 19 expressed concerns to the Department of Labor about the Occupational Safety and Health Administration’s proposed emergency response rule. The…
Headline
Boston Medical Center, a private, not-for-profit, equity-led academic medical center, is the winner of AHA’s 2024 Foster G. McGaw Prize for its leadership and…
Headline
WellSpan Health in York, Pa., will receive the 2024 AHA Quest for Quality Prize for its commitment to improving quality through its health equity strategic…
Headline
Access to quality mental and physical health services can be a complex challenge, but for individuals of color and people with severe or chronic mental…